Meeting
2013 ASCO Annual Meeting
Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.
Authors
Alex A. Adjei
Roswell Park Cancer Institute, Buffalo, NY
Alex A. Adjei , Patricia LoRusso , Antoni Ribas , Jeffrey Alan Sosman , Anna C. Pavlick , Grace K. Dy , Xiaofei Zhou , Esha A. Gangolli , Russell M Walker , Michelle Kneissl , Stephanie Faucette , Rachel Neuwirth , Viviana Bozon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Pharmacology
Clinical Trial Registration Number
NCT00948467
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2528)
DOI
10.1200/jco.2013.31.15_suppl.2528
Abstract #
2528
Poster Bd #
16
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma.
First Author: J. A. Sosman
Poster
2019 ASCO Annual Meeting
A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors.
First Author: Melissa Lynne Johnson
Poster
2018 ASCO Annual Meeting
Vorolanib (CM082) in Chinese patients with advanced solid tumor: A phase 1, open-label, dose escalation study.
First Author: Yan Song
Poster
2018 ASCO Annual Meeting
A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
First Author: Filip Janku